News und Analysen
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung
Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
Southcoast Behavioral Health Expands Services and Capacity
Southcoast Behavioral Health today reinforced its strong commitment to the communities it serves through the addition of a dedicated child and adolescent behavioral health program, expanding the
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (22
DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein
Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Premier Inc. Named One of the 2022 World’s Most Ethical Companies® by Ethisphere® for 15th Consecutive Year
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A P
Pfizer Completes Acquisition of Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several
Pfizer Completes Acquisition of Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several
ICON plc to Webcast Analyst Day Meeting
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will provide a live webcast of its Analyst Day meeting which will take
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 17. März 2022 zu den Ergebnissen des Geschäftsjahres 2021
DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 17. März 2022 zu den Ergebnissen des Geschäftsjahres 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG meldet nicht zahlungswirksame Wertminderung des Geschäfts- oder Firmenwertes von 231 Mio. € nach F&E Konsolidierung; entsprechende Erhöhung des operativen Konzernaufwands in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG meldet nicht zahlungswirksame Wertminderung des Geschäfts- oder Firmenwertes von 231 Mio. € nach F&E Konsolidierung; entsprechende Erhöhung des operativen Konzernaufwands in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
Simulations Plus Releases MembranePlus 3.0
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced it has
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company today announced that its majority-owned digital health subsidiary Veris Health (“Veris”) has